Related Experiment Video
Updated: Apr 28, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Sofosbuvir (Sovaldi) for the treatment of hepatitis C
Brian Lam1, Linda Henry, Zobair Younossi
1Betty and Guy Beatty Liver and Obesity Research Program, Claude Moore Education and Research Building, Fairfax Hospital, Falls Church, VA 22042, USA.
Insights
Sofosbuvir (SOF) is a new direct-acting antiviral for Hepatitis C virus (HCV) infection. Clinical trials show SOF-containing regimens are safe, effective, and well-tolerated across all HCV genotypes, improving patient outcomes.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a significant global health concern causing chronic liver disease.
- Previous treatments like pegylated-interferon and ribavirin had limited efficacy and significant side effects.
- First-generation direct-acting antivirals (DAAs) improved efficacy but introduced new side effects.
Purpose of the Study:
- To review the clinical experience and efficacy of Sofosbuvir (SOF)-containing regimens for Hepatitis C virus (HCV) treatment.
- To evaluate the safety and tolerability profile of SOF in diverse patient populations.
- To highlight the impact of SOF on patient-reported outcomes in HCV management.
Main Methods:
- Review of clinical trial data on Sofosbuvir (SOF) efficacy and safety.
- Analysis of SOF's mechanism of action as an HCV-specific uridine nucleotide analog inhibitor of NS5B polymerase.
- Assessment of patient-reported outcomes from studies involving SOF-based therapies.
Main Results:
- Sofosbuvir (SOF) is an approved HCV treatment in the USA, Canada, and Europe.
- SOF-containing regimens demonstrate high efficacy and safety across all HCV genotypes.
- These regimens are well-tolerated, leading to improved patient-reported outcomes.
Conclusions:
- Sofosbuvir (SOF) represents a significant advancement in Hepatitis C virus (HCV) treatment.
- SOF-based therapies offer a safe and effective option for patients with all HCV genotypes.
- The improved safety and efficacy profile of SOF enhances patient well-being and treatment adherence.
Abstract:
Hepatitis C (HCV) remains an important cause of chronic liver disease worldwide. Historically, treatment included pegylated-interferon and ribavirin with low efficacy and numerous side effects contributing to poor adherence and impairment of patients' well-being. The next step in developing better treatment regimens for HCV led to the development of the first-generation direct acting antivirals (DAAs). Although these DAAs improved efficacy, they also added substantial side effects. The next generation of DAAs include Simeprevir and Sofosbuvir (SOF) which not only further enhanced the efficacy of the regimens but also improve their safety profile. This review summarizes the current clinical experience with SOF. SOF, an HCV-specific uridine nucleotide analog which inhibits the NS5B polymerase, is now available in the USA, Canada and Europe. Clinical trials of SOF-containing regimens have shown that these regimens are safe, efficacious, and well-tolerated in all genotypes. Additionally, SOF is associated with improved patient reported outcomes.
More Related Videos
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
09:11Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Cystic Fibrosis: Management
Sinus disease and chronic...
Retrovirus Life Cycles
Subviral Agents